Skip to main content
NextCell Pharma AB logo

NextCell Pharma AB — Investor Relations & Filings

Ticker · NXTCL ISIN · SE0009723125 LEI · 549300PBFGB5JYKXGA45 ST Manufacturing
Filings indexed 0 across all filing types
Latest filing no filings yet
Country SE Sweden
Listing ST NXTCL

About NextCell Pharma AB

https://nextcellpharma.com/

NextCell Pharma AB is a biopharmaceutical company developing advanced cell therapies for autoimmune diseases. Its lead drug candidate, ProTrans, is a novel stromal cell therapy in Phase II clinical trials for the treatment of type 1 diabetes. ProTrans is based on a patented technology platform for selecting and manufacturing potent cell products. In addition to its therapeutic development, NextCell operates Cellaviva, a private stem cell bank that provides services for the collection and storage of umbilical cord blood and tissue stem cells for future medical use. The company leverages its expertise in advanced cell handling, processing, and logistics for its clinical projects and collaborative services.

Recent filings

No filings indexed yet

We are still gathering filings for NextCell Pharma AB. .

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.